Skip to main content

TransMedics Group, Inc. (TMDX)

NASDAQ: TMDX · Delayed Price · USD
27.15
-0.29 (-1.06%)
After-hours:Oct 22, 2021 6:24 PM EDT
27.44
-0.78 (-2.76%)
At close: Oct 22, 4:00 PM
Market Cap781.04M
Revenue (ttm)29.94M
Net Income (ttm)-29.98M
Shares Out27.62M
EPS (ttm)-1.10
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume140,315
Open27.86
Previous Close28.22
Day's Range26.88 - 28.03
52-Week Range11.51 - 49.50
Beta1.91
AnalystsBuy
Price Target46.40 (+69.1%)
Est. Earnings DateNov 3, 2021

About TMDX

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system tha...

IndustryHealth Care Equipment & Supplies
IPO DateMay 2, 2019
Employees110
Stock ExchangeNASDAQ
Ticker SymbolTMDX
Full Company Profile

Financial Performance

In 2020, TMDX's revenue was $25.64 million, an increase of 8.62% compared to the previous year's $23.60 million. Losses were -$28.75 million, -14.31% less than in 2019.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for TMDX stock is "Buy." The 12-month stock price forecast is 46.40, which is an increase of 69.10% from the latest price.

Price Target
$46.40
(69.10% upside)
Analyst Consensus: Buy

News

TransMedics Receives FDA Approval for its OCS Liver System for Preservation and Assessment of Donor Livers for Transp...

ANDOVER, Mass., Sept. 29, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st...

3 weeks ago - PRNewsWire

TransMedics (TMDX) Receives FDA Nod for OCS Heart System

TransMedics' (TMDX) OCS Heart System is expected to enable broader use of donor hearts for transplantation in the United States.

1 month ago - Zacks Investment Research

TransMedics' OCS Heart System Scores FDA Approval

TransMedics Group Inc (NASDAQ: TMDX) has received FDA premarket approval (PMA) for its OCS Heart system. Related content:  Benzinga's Full  FDA Calendar.

1 month ago - Benzinga

TransMedics Receives FDA Approval for its OCS Heart System Enabling Broader Utilization of Donor Hearts for Transplan...

ANDOVER, Mass., Sept. 7, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...

1 month ago - PRNewsWire

TransMedics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

ANDOVER, Mass., Aug. 26, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...

1 month ago - PRNewsWire

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANDOVER, Mass., Aug. 9, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stag...

2 months ago - PRNewsWire

TransMedics (TMDX) Reports Q2 Loss, Tops Revenue Estimates

TransMedics (TMDX) delivered earnings and revenue surprises of -44.44% and 3.69%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

TransMedics Reports Second Quarter 2021 Financial Results

ANDOVER, Mass., Aug. 5, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stag...

2 months ago - PRNewsWire

TransMedics Receives FDA Clearance of OCS Lung Solution for Cold Preservation of Lungs

ANDOVER, Mass., July 29, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...

2 months ago - PRNewsWire

Will TransMedics (TMDX) Report Negative Earnings Next Week? What You Should Know

TransMedics (TMDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

TransMedics to Participate in the Canaccord Genuity 41st Annual Growth Conference

ANDOVER, Mass., July 28, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...

2 months ago - PRNewsWire

TransMedics to Report Second Quarter 2021 Financial Results on August 5, 2021

ANDOVER, Mass., July 22, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...

3 months ago - PRNewsWire

FDA Advisory Committee Gives Thumbs Up To TransMedics' OCS Liver System

The Gastroenterology and Urology Devices Panel of the FDA's Medical Devices Advisory Committee has issued a favorable vote to support the approval of TransMedics Group Inc's (NASDAQ:TMDX) OCS Liver Syst...

3 months ago - Benzinga

TransMedics Announces Positive FDA Advisory Committee Vote for the OCS Liver System

ANDOVER, Mass., July 14, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...

3 months ago - PRNewsWire

TransMedics Stock Trading Halted Today; FDA Advisory Committee to Review Premarket Approval Application for the OCS L...

ANDOVER, Mass., July 14, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...

3 months ago - PRNewsWire

TransMedics Announces Scheduling of OCS Liver FDA Advisory Committee Meeting

ANDOVER, Mass., June 10, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...

4 months ago - PRNewsWire

TransMedics Announces Presentation of OCS Liver PROTECT Trial Results and is Recognized as Winner of The People's Cho...

ANDOVER, Mass., June 8, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stag...

4 months ago - PRNewsWire

David Abrams Buys 3 Stocks in 1st Quarter

David Abrams (Trades, Portfolio), the leader of Abrams Capital Management, disclosed his first-quarter portfolio earlier this month.

Other symbols:CCOCHNGCTLPNUVBPCGSCU
5 months ago - GuruFocus

TransMedics (TMDX) Reports Q1 Loss, Tops Revenue Estimates

TransMedics (TMDX) delivered earnings and revenue surprises of -3.57% and 1.78%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Recap: TransMedics Group Q1 Earnings

Shares of TransMedics Group (NASDAQ:TMDX) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 30.95% over the past year to ($0.29), whic...

5 months ago - Benzinga

TransMedics Reports First Quarter 2021 Financial Results

ANDOVER, Mass., May 4, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage...

5 months ago - PRNewsWire

1 Feel-Good Healthcare Stock That Could Turn Your Tax Return Into Riches

TransMedics is looking to disrupt an entire industry and help thousands of transplant patients in the U.S. in the process.

6 months ago - The Motley Fool

TransMedics to Report First Quarter 2021 Financial Results on May 4, 2021

ANDOVER, Mass., April 20, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st...

6 months ago - PRNewsWire

TransMedics Stock Is Trading Higher After FDA Adcom Votes In Favor Of Its OCS Heart System

The FDA Advisory Committee has voted in favor of TransMedics Group Inc (NASDAQ: TMDX) after reviewing clinical evidence from the OCS Heart EXPAND trial, the associated Continued Access Protocol (CAP) re...

6 months ago - Benzinga

TransMedics Announces Positive FDA Advisory Committee Vote for OCS Heart System

ANDOVER, Mass., April 6, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...

6 months ago - PRNewsWire